Talha Badar: Prognostic impact of ‘multi-hit’ versus ‘single-hit’ TP53 alteration in patients with AML
Talha Badar posted on X about recent paper by him as first author, titled “Prognostic impact of ‘multi-hit’ versus ‘single-hit’ TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases” published on Haematalogica.
Authors: Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Emily C. Craver, Zhuo Li, Aaron D. Goldberg, Antoine N. Saliba, Anand Patel, Jan P. Bewersdorf, Adam Duvall, Madelyn Burkart, Danielle Bradshaw, Yasmin Abaza, Maximilian Stahl, Neil Palmisiano, Guru Subramanian Guru Murthy, Amer M. Zeidan, Vamsi Kota, Mrinal M. Patnaik, Mark R. Litzow
“Finally available online, free access: Prognostic impact of ‘multi-hit’ versus ‘single-hit’ TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
We analyzed:
1. Impact of allelic burden on outcome including transplant.
2. Outcome with or without complex CG
3. Impact of concurrent somatic mutation on outcome.”
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023